Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MAIA Biotechnology, Inc.

< Previous 1 2 3 Next >
MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present at AACR Annual Meeting 2023
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces No Exposure to Silicon Valley Bank
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
ADDING MULTIMEDIA: MAIA Biotechnology’s Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Advances New Telomere-Targeting Molecule Program
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Participate in Four Upcoming Investor Conferences
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Establishment of Rule 10b5-1 Trading Plan
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Presents Preclinical Data at SITC Annual Meeting Validating Efficacy of THIO in Treating Hepatocellular Carcinoma
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Participate in ThinkEquity Conference
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Closing of Initial Public Offering
From MAIA Biotechnology, Inc.
Via Business Wire
Tickers MAIA
MAIA Biotechnology Announces Pricing of Initial Public Offering
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Doses First Patient With THIO in Phase 2 Trial (THIO-101) for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology, Inc. Announces Research Collaboration with Nationwide Children’s Hospital to Evaluate THIO in Combination with Standard-of-Care Cancer Therapies
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology, Inc. Establishes Wholly Owned Subsidiaries in Romania and Australia to Support Global Development of THIO
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology, Inc. Announces FDA Orphan Drug Designation for THIO for the Treatment of Hepatocellular Carcinoma (HCC)
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology, Inc. Announces $2.4 Million Financing to Advance Targeted Immuno-Oncology Studies
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC
From MAIA Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.